"Oh gee, what a surprise—THC levels are inflated."

This comment, mentioned by Pierre Killeen during a recent Qredible Live broadcast, reflects the growing awareness among cannabis consumers that product labels often don't tell the whole truth. According to Killeen, Executive Director of the Cannabis Standards Alliance of Canada (CSAC), a 2025 study discussed in the cannabis industry revealed a significant problem: 28% of tested products contained only 70-80% of their advertised THC content, with THC levels in 46 products measuring 9-48% lower than their labels claimed.

This isn't just a Canadian problem. Similar patterns of THC inflation plague the American market, creating what Pierre Killeen describes as "a crisis of consumer trust."

The consequences? Companies trying to be honest about their THC content watch sales decline as consumers chase exaggerated numbers from competitors—a market that perversely punishes truth and rewards deception.

Why Cannabis Companies Resist Addressing Label Accuracy

When asked why the industry seems reluctant to fix this problem, Killeen identifies several key factors:

"This is a collective action problem," Killeen explains. "One part of the industry acting independently is not going to solve this problem."

He notes that companies doing the right thing often suffer market consequences: "I know specifically just talking about one of your members...a very respected cannabis brand...they experienced declining sales in 2023 as consumers gravitated towards the competitors' inflated claims because they were trying to do the right thing."

Even when consumers recognize the issue—with many on platforms like Reddit expressing no surprise about inflated THC numbers—the market incentives still push toward inaccurate labeling.

The Root Causes Behind THC Inflation

The problem goes deeper than simple deception. According to Killeen, several systemic issues contribute:

1. Regulatory frameworks that emphasize THC content - "Up here, you walk into a dispensary, you see a display board and you see the names of these products and you see the THC number...and then you see price...automatically that's the construct with which a consumer starts to make decisions."
2. Lack of standardized sampling procedures - "There is no shared definition on the operator side of how to collect a representative sample for the purposes of testing."
3. Inconsistent laboratory testing methods - "There are no rules governing how samples are prepared for laboratory testing."

CSAC's Approach to Self-Regulation

Rather than waiting for regulators to address these problems, CSAC is developing industry-led standards:

"We've spent the last four, five, six months bringing experts together from across our membership to engage in conversations about developing best practices in sampling that can then be turned into a standard," Killeen shares.

This collaborative approach includes:

1. Creating detailed standards for collecting representative samples - "We've got a sampling standard for operators."
2. Developing laboratory protocols for consistent testing - "We've focused on the development of a standard for preparing a representative sample for testing cannabinoids in cannabis flour."
3. Planning proof-of-concept testing - "We're going to run a proof of concept...that will demonstrate when these standards operate in tandem that they can yield accurate and transparent and consistent results across multiple players."
4. Establishing certification for compliant products - "That is going to put us in a position to basically certify products."

Shift the Industry Conversation

Killeen emphasizes that the industry's THC fixation misses what's truly valuable about cannabis:

"There's much more to the plant, the power of the plant than that cannabinoid," he notes, adding that the current regulatory framework has "been a real contributor to this THC obsession."

The goal is to broaden consumer understanding beyond THC percentages to encompass the full therapeutic value of cannabis products.

A Hybrid Public-Private Approach

Killeen suggests that traditional regulatory approaches are inadequate for the cannabis industry:

"Our regulatory tool set is really based on industrial age technology. We find ourselves at a time and in an industry which evolves so quickly that that old tool set's never going to be able to deal with so many of the issues and challenges."

Instead, he advocates for what he calls a "hybrid private-public partnership":

"The solution is this sort of hybrid private-public partnership around regulating this industry. The rules that we develop are based on industry best practices, with the leaders in the industry coming together to say these are the best practices that we can then standardize."

Build a Trusted Cannabis Marketplace

For cannabis businesses concerned about market integrity, participating in self-regulation efforts offers a path toward building consumer trust while creating a more level playing field.

"We have this our industry needs a shared set of rules, oversee compliance with those in order to create a business environment that is more conducive to financial sustainability of companies and social responsibility of companies," explains Killeen.

The work of organizations like CSAC shows the industry can develop solutions from within—establishing standards that benefit producers, patients, and the broader market. By addressing the THC inflation issue through collaborative standards and certification, the cannabis industry can build a marketplace founded on accuracy and transparency rather than marketing hype.